A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine with 5- and/or 10-year Booster Doses in Children and Adolescents who had been Primed with MenACYW Conjugate Vaccine as Toddlers

Meningococcal infection

Vaccine seroresponse against meningococcal serogroups A, C, W, and Y

Antibody titers against meningococcal serogroups A, C, W, and Y before the administration of a booster dose of MenACYW conjugate vaccine (Group 1 and 2), Antibody titers against meningococcal serogroups A, C, W, and Y at Visit 2 (Group 2), Antibody titers against meningococcal serogroups A, C, W, and Y at Visit 3 (Group 1), Antibody titers against meningococcal serogroups A, C, W, and Y at Visit 1 and Visit 2 (Group 1), Antibody titers against meningococcal serogroups A, C, W, and Y at Visit 2 and Visit 3 (Group 2), Antibody titers against meningococcal serogroups A, C, W, and Y at Visit 3 and Visit 4 (Group 1), Antibody concentrations against tetanus toxoid at Visit 1 and Visit 2 (Group 1), Antibody concentrations against tetanus toxoid at Visit 3 and Visit 4 (Group 1), Antibody concentrations against tetanus toxoid at Visit 2 and Visit 3 (Group 2), Antibody titers against meningococcal serogroup C Visit 3 and Visit 4 (Group 1), Antibody titers against meningococcal serogroup C Visit 2 and Visit 3 (Group 2), Number of participants with immediate unsolicited systemic adverse events (AEs), Number of participants with solicited injection site reactions and systemic reactions, Number of participants with unsolicited AEs, Number of participants with serious adverse events (SAEs) and Adverse Event of Special Interest (AESI)

No related papers found yet.

Finland, Germany, Hungary, Spain